Selective cyclooxygenase-2 inhibition prevents alveolar bone loss in experimental periodontitis in rats

Journal of Periodontology

Volumn 71, Issue 6, 2000, Pages 1009-1014

  Bezerra, Mirna M ^a   De Lima, Vilma ^a   Alencar, Veruska B M ^a   Vieira, Ivana B ^b   Brito, Gerly Anne C ^b   Ribeiro, Ronaldo A ^a   Da Rocha, Francisco Airton Castro ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b Universidade Federal do Ceará ^*

Author keywords

Alveolar bone loss prevention and control; Animal studies; Cyclooxygenase inhibitors therapeutic use; Dental models; Prostaglandins adverse effects

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; MELOXICAM;

ALVEOLAR BONE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; LYMPHOCYTOSIS; MALE; NEUTROPHILIA; NONHUMAN; OSTEOLYSIS; PERIODONTITIS; RAT;

EID: 0033855163     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2000.71.6.1009     Document Type: Article

References (22)

1. 2 secretion as a determinant of periodontal disease expression. J Periodontol 1993;64:432-444.
2. Raisz LG. The role of prostaglandins in the local regulation of bone metabolism. Prog Clin Biol Res 1990; 332:195-203.
3. Williams RC, Jeffcoat MK, Howell TH, et al. Three-year trial of flurbiprofen treatment in humans - post treatment period. J Dent Res 1991;70:468-472.
4. Spangler RS. Cyclooxygenase 1 and 2 in rheumatic disease: Implications for non-steroidal anti-inflammatory drug therapy. Semin Arthritis Rheum 1996;26:435-446.
5. Vane JR. Towards a better aspirin. Nature 1994;367:215-216.
6. Vane JR, Botting RM. Mechanisms of action of anti-inflammatory drugs. Scand J Rheumatol 1996;25(Suppl. 102):9-21.
7. Engelhardt G, Homma D, Schlegel K, Schnitzler CHR, Utzmann R, Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favorable gastrointestinal tolerance. Inflamm Res 1995;44:423-433.
8. Engelhardt G. Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Br J Reumatol 1996;35(Suppl. 1):4-12.
9. Sallay K, Sanavi F, Ring I, Pham P, Behling UH, Nowotny A. Alveolar bone destruction in the immunosuppressed rat. J Periodont Res 1982;17:263-274.
10. Crawford JM, Taubman MA, Smith DJ. The natural history of periodontal bone loss in germ-free and gnotobiotic rats infected with periodontopathic microorganisms. J Periodont Res 1978;13:316-325.
11. Szabo S, Teier JS, Brown A, Schmoor J, Homan HD, Bradford JC. A quantification method for assessing the extent of experimental erosions and ulcers. J Pharmacol Meth 1985;13:59-66.
12. Schroeder HE, Lindhe J. Conversion of stable established gingivitis in the dog into destructive periodontitis. Arch Oral Biol 1975;20:775-779.
13. Keyes PH, Jordan HV. Periodontal disease in the Syrian hamster. Findings related to an infectious and transmissible component. Arch Oral Biol 1964;9:377-400.
14. Nyman S, Schroeder HE, Lindhe J. Suppression of inflammation and bone resorption by indomethacin during experimental periodontitis in dogs. J Periodontol 1979;50:450-461.
15. Lasfargues JJ, Saffar JL. Effect of indomethacin on bone destruction during experimental periodontal disease in the hamster. J Periodont Res 1983;18:110-117.
16. Howell TH, Williams RC. Non-steroidal anti-inflammatory drugs as inhibitor of periodontal disease progression. Crit Rev Oral Biol Med 1993;4:177-196.
17. Lindemann RA, Economou JS, Rothermel H. Production of interleukin-1 and tumor necrosis factor by human peripheral monocytes activated by periodontal bacteria and extracted lipopolysaccharides. J Dent Res 1988;67: 1131-1135.
18. El Attar TMA, Lin HS, Killoy WJ, Vanderhoek JY, Goodson JM. Hydroxy fatty acids and prostaglandin formation in diseased human periodontal pocket tissue. J Periodont Res 1986;21:169-172.
19. Rainsford KD. Non-steroidal anti-inflammatory drugs. In: Dale MM, Foreman JC, Fan T-PD, eds. Textbook of Immunopharmacology, 3rd ed. Oxford: Blackwell Scientific Publications; 1994:309-319.
20. Engelhardt G, Bögel R, Schnitzer CHR, Utzmann R. Meloxicam: Influence on arachidonic acid metabolism. Part II. "In vivo" findings. Biochem Pharmacol 1996;51: 29-38.
21. Distel M, Mueller C, Bluhmki E. Global analysis of gastrointestinal safety of a new MSAID, meloxicam. Inflammopharmacol 1996;4:71-78.
22. Jouzeau JY, Terlain B, Abid A, Nédélec E, Netter P. Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 1997;53:563-582.